Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

84
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
84
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Efficacy Of Anamorelin In Advanced Pancreatic Cancer Patients With A Poor Performance Status.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Efficacy Of Anamorelin In Advanced Pancreatic Cancer Patients With A Poor Performance Status.

Related Experiment Video

Laparoscopic Posterior Radical Antegrade Modular Pancreatosplenectomy for Distal Pancreatic Carcinoma
03:55

Laparoscopic Posterior Radical Antegrade Modular Pancreatosplenectomy for Distal Pancreatic Carcinoma

Published on: December 29, 2023

441

Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with a Poor Performance Status.

Tsuyoshi Takeda1, Takashi Sasaki1, Takeshi Okamoto1

  • 1Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Japan.

Internal Medicine (Tokyo, Japan)
|June 19, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Anamorelin showed limited efficacy in pancreatic cancer patients with poor performance status (PS). Patients with good PS responded better, while poor PS was linked to shorter treatment and survival.

Keywords:
anamorelinanorexiacachexiapancreatic cancer

More Related Videos

Application of Mid-Pancreatectomy with End-to-End Anastomosis in Pancreatic Benign Tumors
02:20

Application of Mid-Pancreatectomy with End-to-End Anastomosis in Pancreatic Benign Tumors

Published on: February 9, 2024

321
Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer
06:20

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Published on: October 4, 2022

2.7K

Related Experiment Videos

Laparoscopic Posterior Radical Antegrade Modular Pancreatosplenectomy for Distal Pancreatic Carcinoma
03:55

Laparoscopic Posterior Radical Antegrade Modular Pancreatosplenectomy for Distal Pancreatic Carcinoma

Published on: December 29, 2023

441
Application of Mid-Pancreatectomy with End-to-End Anastomosis in Pancreatic Benign Tumors
02:20

Application of Mid-Pancreatectomy with End-to-End Anastomosis in Pancreatic Benign Tumors

Published on: February 9, 2024

321
Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer
06:20

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Published on: October 4, 2022

2.7K

Area of Science:

  • Oncology
  • Gastroenterology
  • Pharmacology

Background:

  • Pancreatic cancer (PC) cachexia management is challenging.
  • Previous anamorelin trials excluded patients with poor performance status (PS).
  • Efficacy in PC patients with poor PS remains uncertain.

Purpose of the Study:

  • To evaluate anamorelin efficacy in PC patients with poor PS (2) versus good PS (0-1).
  • To compare response rates, treatment duration, early discontinuation, and overall survival.

Main Methods:

  • Retrospective review of 45 PC patients with cachexia receiving anamorelin.
  • Primary outcome: proportion of responders (maintained/gained weight/appetite over 12 weeks).
  • Secondary outcomes: treatment duration, early discontinuation, overall survival.
performance status

Main Results:

  • Responders were significantly fewer in poor PS (0%) vs. good PS (37%) groups (p=0.042).
  • Poor PS associated with shorter anamorelin duration (14 vs. 93 days), higher early discontinuation (70% vs. 17%), and reduced survival (62 vs. 188 days).
  • Moderate weight loss and pancreatic enzyme therapy correlated with response.

Conclusions:

  • Anamorelin efficacy is very limited in pancreatic cancer patients with poor performance status.
  • Patients with poor PS are likely not suitable candidates for anamorelin compared to those with good PS.